• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤特异性、HLA 限制性人 CD8 + 细胞溶解性 T 淋巴细胞的体外扩增。

In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.

作者信息

Nakashima M, Watanabe T, Koprowski H, Schuchter L, Steplewski Z

机构信息

Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104-4268.

出版信息

Cell Immunol. 1994 Apr 15;155(1):53-61. doi: 10.1006/cimm.1994.1101.

DOI:10.1006/cimm.1994.1101
PMID:7513262
Abstract

The effect of cytokines with human recombinant interleukin-2 (rIL-2) on cytolytic T cell (CTL) generation was studied. Lymphocytes were isolated from involved lymph nodes of melanoma patients and expanded in medium containing rIL-2 alone or in combination with other human cytokines (rIL-1, rIL-4, rIL-6, and recombinant human tumor necrosis factor-alpha (rTNF alpha)). Lymphocytes incubated with rIL-2 alone did not grow, whereas addition of the other cytokines augmented IL-2-mediated lymphocyte proliferation. In all cultures, the majority of expanded lymphocytes were CD3+, CD56- T cells. Lymphocytes cultured with rIL-1, rIL-2, rIL-4, and rIL-6 exhibited cytolytic activity specific for autologous melanoma, which increased during the culture period (24.08 and 58.18% at 16 and 30 days in culture, respectively) without detectable changes in cell surface phenotype and remained high even after 100 days in culture. Moreover, the cytolytic activity was inhibited by monoclonal antibodies (mAbs) against HLA-class I, CD3, and CD8 molecules but not by mAbs against HLA-class II or CD4 molecules. Lymphokine-activated killer (LAK) activity was detected in lymphocytes cultured with rIL-1, rIL-2, and rIL-6 in the presence or absence of rTNF alpha. These data indicate that lymphocytes derived from melanoma-invaded lymph nodes and cultured in the presence of rIL-1, rIL-2, rIL-4, and rIL-6 offers an efficient system to expand CD8+ CTLs with HLA-restricted cytolytic specificity against autologous tumor cells.

摘要

研究了细胞因子与人重组白细胞介素-2(rIL-2)对细胞毒性T细胞(CTL)生成的影响。从黑色素瘤患者受累淋巴结中分离淋巴细胞,并在单独含有rIL-2或与其他人类细胞因子(rIL-1、rIL-4、rIL-6和重组人肿瘤坏死因子-α(rTNFα))组合的培养基中进行扩增。单独用rIL-2孵育的淋巴细胞不生长,而添加其他细胞因子可增强IL-2介导的淋巴细胞增殖。在所有培养物中,大多数扩增的淋巴细胞是CD3 +、CD56 - T细胞。用rIL-1、rIL-2、rIL-4和rIL-6培养的淋巴细胞表现出对自体黑色素瘤的细胞溶解活性,在培养期间这种活性增加(培养16天和30天时分别为24.08%和58.18%),细胞表面表型无明显变化,甚至在培养100天后仍保持高水平。此外,细胞溶解活性受到针对HLA-I类、CD3和CD8分子的单克隆抗体(mAb)的抑制,但不受针对HLA-II类或CD4分子的mAb的抑制。在用rIL-1、rIL-2和rIL-6培养的淋巴细胞中,无论有无rTNFα,均检测到淋巴因子激活的杀伤(LAK)活性。这些数据表明,源自黑色素瘤侵袭淋巴结并在rIL-1、rIL-2、rIL-4和rIL-6存在下培养的淋巴细胞提供了一个有效的系统,可扩增具有针对自体肿瘤细胞的HLA限制性细胞溶解特异性的CD8 + CTL。

相似文献

1
In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.肿瘤特异性、HLA 限制性人 CD8 + 细胞溶解性 T 淋巴细胞的体外扩增。
Cell Immunol. 1994 Apr 15;155(1):53-61. doi: 10.1006/cimm.1994.1101.
2
Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.用于从外周血淋巴细胞诱导抗原特异性细胞溶解T淋巴细胞的细胞因子组合。
Anticancer Res. 1995 May-Jun;15(3):655-60.
3
Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.固定化抗CD3单克隆抗体诱导同种反应性细胞溶解T淋巴细胞。人细胞溶解T淋巴细胞分化需求分析。
Immunology. 1990 Jul;70(3):357-64.
4
Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.用双特异性单克隆抗体扩增的CD4+和CD8+肿瘤浸润淋巴细胞的特性分析。
J Immunol. 1989 Nov 15;143(10):3404-11.
5
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.腹腔注射重组干扰素-γ和重组白细胞介素2(伴或不伴肿瘤浸润淋巴细胞)对卵巢癌或腹膜癌患者的临床及生物学效应
Clin Cancer Res. 2000 Jun;6(6):2268-78.
6
Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.人肾细胞癌中CD4 +和CD8 +肿瘤浸润淋巴细胞的细胞溶解活性特征
Cancer Res. 1990 Apr 15;50(8):2363-70.
7
Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.大多数源自人黑色素瘤浸润淋巴细胞的 CD8+ 和 CD4+ 肿瘤特异性 T 细胞克隆在体外对自体肿瘤细胞反应时产生有缺陷的淋巴因子。
Eur J Immunol. 1994 Sep;24(9):1966-73. doi: 10.1002/eji.1830240905.
8
HLA-B-restricted, CD8+ cytolytic human T cell clones derived from a melanoma-invaded lymph node.源自黑色素瘤侵袭淋巴结的HLA - B限制性、CD8 + 细胞溶解性人T细胞克隆。
Hybridoma. 1996 Apr;15(2):147-54. doi: 10.1089/hyb.1996.15.147.
9
Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.人类T细胞的主要组织相容性复合体非限制性细胞溶解活性。前体频率和效应表型分析。
J Immunol. 1987 Dec 1;139(11):3886-95.
10
Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.抗CD3和抗CD28抗体对白细胞介素-2激活的外周血单个核细胞的表型和功能调节
Lymphokine Cytokine Res. 1993 Aug;12(4):191-6.

引用本文的文献

1
Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.从外周血中诱导出针对肿瘤细胞的自体人细胞毒性T淋巴细胞(CTL)。
Cytotechnology. 1997 Jan;23(1-3):197-203. doi: 10.1023/A:1007995013870.
2
High rate of induction of human autologous cytotoxic T lymphocytes against renal carcinoma cells cultured with an interleukin cocktail.用人白细胞介素鸡尾酒培养的肾癌细胞诱导人自体细胞毒性T淋巴细胞的高诱导率。
Jpn J Cancer Res. 1998 Nov;89(11):1195-201. doi: 10.1111/j.1349-7006.1998.tb00515.x.
3
Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18.
白细胞介素-18对人CD8 + 细胞毒性T淋巴细胞的直接激活作用
Jpn J Cancer Res. 1998 Oct;89(10):1041-6. doi: 10.1111/j.1349-7006.1998.tb00494.x.
4
Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells.从外周血单个核细胞诱导的人细胞毒性T淋巴细胞的长期无血清/无血浆培养。
Cancer Immunol Immunother. 1994 Nov;39(5):279-85. doi: 10.1007/BF01519979.